Scarica l'app Stockscreener
27.81
2.92%
0.79
Dopo l'orario di chiusura:
27.81
Precedente Chiudi:
$27.02
Aprire:
$27.36
Volume 24 ore:
499.45K
Relative Volume:
0.76
Capitalizzazione di mercato:
$1.83B
Reddito:
-
Utile/perdita netta:
$-137.95M
Rapporto P/E:
-11.02
EPS:
-2.5226
Flusso di cassa netto:
$-107.11M
1 W Prestazione:
+2.43%
1M Prestazione:
+3.50%
6M Prestazione:
+65.83%
1 anno Prestazione:
+136.68%
Intervallo 1D:
$27.36
$28.92
Intervallo di 1 settimana:
$26.68
$28.92
Portata 52W:
$9.57
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
27.81 | 1.78B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Iniziato | BofA Securities | Buy |
| 2026-01-29 | Iniziato | Citizens JMP | Mkt Perform |
| 2026-01-08 | Iniziato | BTIG Research | Buy |
| 2025-12-18 | Iniziato | Mizuho | Neutral |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
BlackRock (BCAX holder) discloses 5.4% Bicara Therapeutics stake on Schedule 13G - Stock Titan
Bicara Therapeutics Inc (BCAX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bicara Therapeutics Inc (BCAX) Balance Sheet - TradingKey
Bicara Therapeutics Inc (BCAX) Income Statement - TradingKey
Bicara Therapeutics Inc (BCAX) Cash Flow - TradingKey
Bicara Therapeutics Inc (BCAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bicara Therapeutics Inc (BCAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BCAX|Bicara Therapeutics Inc|Price:27.020|Chg%:-0.710 - TradingKey
Bicara Therapeutics Inc (BCAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bicara Therapeutics (BCAX) Hovers Near Support Amid Modest DeclineProfit Surge Picks - dars.gov.et
Bicara Therapeutics (BCAX) Corporate presentation Summary - Quartr
Bicara Therapeutics (BCAX) Proxy filing Summary - Quartr
Bicara Therapeutics (BCAX) Study update Summary - Quartr
Bicara Therapeutics (BCAX) Q1 2026 earnings summary - Quartr
Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com - Investing.com South Africa
Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock - Investing.com Nigeria
Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock By Investing.com - Investing.com India
Form 4 Bicara Therapeutics Inc For: 14 July - Investing.com India
Bicara Therapeutics (BCAX) CEO exercises options and sells 10,000 shares under 10b5-1 plan - Stock Titan
Enterprise value to revenue forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Extended Trial Data And Insider Sale Could Be A Game Changer For Bicara Therapeutics (BCAX) - Sahm
Bicara therapeutics president & COO sells $833k in stock By Investing.com - Investing.com India
Bicara Therapeutics CFO Hyep Ivan sells $807k in stock By Investing.com - Investing.com India
Form 144 Bicara Therapeutics Inc. For: 10 July By Investing.com - Investing.com Nigeria
Enterprise value to EBIT forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Form 4 Bicara Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Bicara Therapeutics CFO Hyep Ivan sells $807k in stock - Investing.com
Bicara therapeutics president & COO sells $833k in stock - Investing.com
Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing - marketscreener.com
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) COO exercises options, sells 28,750 shares under plan - Stock Titan
Price to sales forward of Bicara Therapeutics Inc. – BOATS:BCAX - TradingView
Price to book forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Form 144 BICARA THERAPEUTICS INC. For: 8 July By Investing.com - Investing.com Nigeria
Form 144 Bicara Therapeutics Inc. For: 8 July By Investing.com - Investing.com Nigeria
BCAX (NASDAQ) insider sales: 50,000-share option exercise set for 07/08/2026 - Stock Titan
Sale notice: 28,750 shares disclosed by BCAX (NASDAQ: BCAX) - Stock Titan
BCAX (NASDAQ) affiliate files Rule 144; past sales of 9,200 shares noted - Stock Titan
Bicara Therapeutics (BCAX) Piper Sandler 37th Annual Healthcare Conference Summary - Quartr
Form 144 BICARA THERAPEUTICS INC. For: 7 July By Investing.com - Investing.com Nigeria
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):